Product Details

Tenofovir + Lamivudine Tablets BP 600 mg deliver a high-quality combination therapy that meets British Pharmacopoeia (BP) standards. This fixed-dose combination manages HIV-1 infection as part of a broader antiretroviral treatment regimen, combining dual nucleoside/nucleotide reverse transcriptase inhibitor action in a single film-coated tablet.

The tablets combine:

• Tenofovir Disoproxil Fumarate, a nucleotide reverse transcriptase inhibitor (NtRTI) that blocks HIV viral replication by inhibiting reverse transcriptase enzyme activity, and
• Lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI) that suppresses HIV viral replication through the same reverse transcriptase inhibition pathway, working synergistically with Tenofovir.

Doctors commonly prescribe this combination as part of a combination antiretroviral therapy (cART) regimen for HIV-1 infection management. Hospitals, specialty clinics, and pharmacies rely on this formulation for its consistent quality and dependable therapeutic results. Our manufacturing process follows strict quality standards to guarantee high purity, accurate dosing, and reliable therapeutic efficacy in every batch.

Key Features

• BP-standard compliant combination therapy
• Supports HIV-1 management as part of antiretroviral therapy
• Delivers dual NtRTI/NRTI antiretroviral action
• Contains Tenofovir Disoproxil 300 mg + Lamivudine 300 mg per film-coated tablet
• Maintains a high-purity, stable formulation
• Uses hygienic blister packaging for safe storage
• Suits hospital, specialty clinic, and pharmacy use